D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients

American Journal of Psychiatry

Volumn 152, Issue 10, 1995, Pages 1444-1449

  Nordström, Anna Lena ^a,b   Farde, Lars ^a   Nyberg, Svante ^a   Karlsson, Per ^a   Halldin, Christer ^a   Sedvall, Göran ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLSPIPERONE; CLOZAPINE; RACLOPRIDE; RADIOLIGAND; SEROTONIN RECEPTOR; 3-N-METHYLSPIPERONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE RECEPTOR; DRUG DERIVATIVE; SALICYLAMIDE DERIVATIVE; SPIPERONE;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; DOSE RESPONSE; DRUG MONITORING; GAS CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; BLOOD; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; MALE; METABOLISM; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; BRAIN; CLOZAPINE; FEMALE; HUMAN; MALE; MIDDLE AGE; RACLOPRIDE; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SALICYLAMIDES; SCH-23390; SCHIZOPHRENIA; SPIPERONE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0028991822     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.152.10.1444     Document Type: Article

References (36)

1. Casey DE: Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989; 99(suppl):S47-S53
2. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789-796
3. van Rossum JM: The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966; 160:492-494
4. Farde L, Hall H, Ehrin E, Sedvall G: Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231:258-261
5. 18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry 1988; 23: 653-663
6. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B: Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl) 1989; 99:463-472
7. Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G: PET-analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine-relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
8. Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55(Sept suppl B):47-52
9. Nordström A-L, Farde L, Halldin C: High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl) 1993; 110:365-367
10. Hasegawa M, Gutierrez-Esteinou R: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13: 383-390
11. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B, Telford J, Pion L, Pion H, Park L, Chang Y-J, Oldroyd J, Cooper TB: Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55(Sept suppl B): 133-136
12. Miller DD, Fleming F, Holman TL, Perry PJ: Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994; 55(Sept suppl B):117-121
13. Fleischhacker WW, Hummer M, Kurz M, Kurtzthaler I, Lieberman JA, Pollack S, Safferman AZ, Kane JM: Clozapine dose in the United States and Europe: implications for the therapeutic and adverse effects. J Clin Psychiatry 1994; 55(Sept suppl B):78-81
14. Karlsson P, Farde L, Halldin C, Nordström A-L, Sedvall G: D1-dopamine receptor binding in drug naive schizophrenic patients measured by PET (abstract). J Cereb Blood Flow Metab 1993; 13(suppl 1):S556
15. Nordström A-L, Farde L, Eriksson L, Halldin C: No elevated D2 dopamine receptors in neuroleptic naive schizophrenic patients revealed by PET and [11C]NMSP. Psychiatry Res (in press)
16. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
17. Litton JE, Holte S, Eriksson L: Evaluation of the Karolinska new positron camera system: the Scanditronix PC2048-15B. IEEE Transactions on Nuclear Science 1990; 37:743-748
18. Halldin C, Stone-Elander S, Farde L, Ehrin E, Fasth K-J, Långström B, Sedvall G: Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Rad Appl Instrum [A] 1986; 37:1039-1043
19. Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberger A, Solin O: A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides: preparation and in vitro dopamine D-2 receptor binding. Int J Rad Appl Instrum [B] 1991; 18:871-881
20. Dannals RF, Ravert HT, Wilson AA, Wagner HN Jr: An improved synthesis of (3-N-[11C]methyl)spiperone. Int J Rad Appl Instrum [A] 1986; 37:433-434
21. Farde L, Wiesel F-A, Halldin C, Sedvall G: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45:71-76
22. Farde L, von Bahr C: Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand Suppl 1990; 358:67-71
23. 2 and D2 dopamine receptor occupancy in the living human brain: a PET study with rispendone. Psychopharmacology (Berl) 1993; 110:265-272
24. Bondesson U, Lindström LH: Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology (Berl) 1988; 95:472-475
25. Clark A: General pharmacology, in Handbook of Experimental Pharmacology, vol 4. Berlin, Springer-Verlag, 1937
26. Press WH: Numerical Recipes in C: The Art of Scientific Computing, 2nd ed. New York, Cambridge University Press, 1993, pp 656-706
27. Gerlach J, Hansen L: Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiatry Suppl 1992; 17:34-37
28. Karlsson P, Smith L, Farde L, Härnryd C, Sedvall G, Wiesel F-A: Failure to demonstrate antipsychotic effect of the dopamine D1-receptor antagonist SCH39166 in schizophrenic patients (abstract). European Psychiatry 1994; 9(suppl 1):55
29. Meltzer HY: The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 1992; 160:22-29
30. i values. J Pharmacol Exp Ther 1989; 251: 238-246
31. 2-receptor occupancy studies and clinical response. Br J Psychiatry Suppl (in press)
32. 2 receptors and antipsychotic drugs studied with PET in schizophrenia: preliminary results. Anales de Psiquiatria 1992; 8(suppl 1):9
33. Nordström A-L, Farde L, Wiesel F-A, Forslund K, Pauli S, Halldin C, Uppfeldt G: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33: 227-235
34. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS: Mechanism of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991; 4:121-156
35. Hall H, Halldin C, Nyberg S, Farde L, Sedvall G: Effect of clozapine and rispendone on 5-HT2 and D2-dopamine receptor binding in the post mortem human brain: an autoradiographic study. Eur Neuropsychopharmacol 1994; 5:19-25
36. Bleehen T (ed): Clozapine: Literature Review. Basel, Switzerland, Sandoz Pharma, 1993